Founded in 2019, ArsenalBio is a privately held company that aims to create highly effective and accessible immune cell therapies for a broader number of patients, initially those with cancer. The company integrates technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to discover and develop immune cell therapies. ArsenalBio's programmable and computationally driven approach aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs, and expanded market access. The company's cellular drug discovery tools enable hospitals to create T-cell medicines for cancer treatment. ArsenalBio's team is engineering living medicines to attack cancer's inherent multi-faceted nature and bring dramatic improvements to the lives of patients.